CASI Pharmaceuticals (CASIF) EBITDA Margin (2022 - 2025)
CASI Pharmaceuticals (CASIF) reported EBITDA Margin of 1068.86% for Q4 2025, down 155544.0% on a YoY basis from N/an in Q4 2024, and down 201.15% quarter-over-quarter from 354.93% in Q3 2025.
CASI Pharmaceuticals (CASIF) EBITDA Margin (2022 - 2025) Analysis & Trends
CASI Pharmaceuticals has reported EBITDA Margin for 4 years, with the latest figure at 1068.86% in Q4 2025.
- For the quarter ending Q4 2025, EBITDA Margin fell 155544.0% year-over-year to 1068.86%; the trailing twelve-month figure through Dec 2025 stood at 544.12% (down 74980.0% YoY), and the FY2025 full-year result was 217.3%, down 35688.0% from the prior year.
- EBITDA Margin for Q4 2025 stood at 1068.86%, down from 354.93% in the prior quarter.
- The five-year high for EBITDA Margin was 725.84% in Q4 2023, with the low at 1068.86% in Q4 2025.
- Historically, EBITDA Margin has averaged 90.0% across 4 years, with a median of 116.53% in 2023.
- Annual changes were most pronounced in 2023 — EBITDA Margin jumped 89578 bps — and 2025, when it sank 155544 bps.
- CASI Pharmaceuticals' EBITDA Margin stood at 169.94% in 2022, then soared by 527 bps to 725.84% in 2023, then plunged by 33 bps to 486.58% in 2024, then slumped by 320 bps to 1068.86% in 2025.
- The last three EBITDA Margin figures came in at 1068.86% (Q4 2025), 354.93% (Q3 2025), and 320.65% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 860,679.92 Bn | 860,679.89 Bn | - | - |
| 2 | Belite Bio | 55,284.00 Bn | 55,284.00 Bn | - | - |
| 3 | Quantum Biopharma | 16,206.94 Bn | 16,206.93 Bn | - | - |
| 4 | Legend Biotech | 3,318.00 Bn | 3,317.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,543.84 Bn | 1,543.84 Bn | - | - |
| 6 | Evaxion A | 1,449.11 Bn | 1,449.09 Bn | - | - |
| 7 | Psyence Biomedical | 216.99 Bn | 216.98 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 115.22 Bn | 107.97 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 90.58 Bn | 90.58 Bn | - | - |
| 10 | CASI Pharmaceuticals | - | - | 3.69 Mn | -1,068.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,068.86% |
| Sep 30, 2025 | -354.93% |
| Jun 30, 2025 | -320.65% |
| Mar 31, 2025 | -179.55% |
| Dec 31, 2024 | 486.58% |
| Sep 30, 2024 | -108.34% |
| Jun 30, 2024 | -182.99% |
| Mar 31, 2024 | 276.68% |
| Dec 31, 2023 | 725.84% |
| Sep 30, 2023 | -52.47% |
| Jun 30, 2023 | -124.71% |
| Mar 31, 2023 | -67.49% |
| Dec 31, 2022 | -169.94% |
| Sep 30, 2022 | -79.80% |
| Jun 30, 2022 | -129.05% |
| Mar 31, 2022 | -90.33% |